Atrial fibrillation (AF), the most prevalent cardiac arrhythmia, is estimated to affect 1.5 to 2.0% of the general population, i.e., at least 100 million people worldwide. 1 Left untreated, patients with nonvalvular AF (NVAF) are exposed to an annual risk of thromboembolic stroke of approximately 5%, resulting in 5 million AF-related strokes each year. 1 Properly dosed anticoagulation (e.g., warfarin adjusted to an international normalized ratio [INR] of 2.0 to 3.0)
is extremely effective in preventing AF-related strokes, reducing risk by two-thirds compared with no therapy, and by one-half compared to aspirin. 1 In contrast, aspirin alone achieves a 21%
relative reduction in risk of nonfatal stroke compared with no treatment, and aspirin plus clopidogrel yields an additional 11% reduction compared to aspirin alone. 1 Thus, anticoagulation is the unchallenged current treatment of choice for patients with NVAF at moderate to high risk of thromboembolic complications.
Whether patients with NVAF for whom oral anticoagulation (OAC) is indicated and who
have stable atherothrombotic vascular disease should also use low-dose aspirin to prevent major coronary events is still debated, because the efficacy and safety of combining antiplatelet and anticoagulant agents have not been adequately tested in this clinical setting. 1 A systematic review and meta-analysis of 10 randomized controlled trials comparing combined aspirin-OAC therapy with OAC alone in 4180 patients, in whom OAC was administered to achieve the same target INR or was given at the same fixed dose in both treatment arms, found that combined aspirin-OAC therapy was associated with one-third lower risk of vascular events compared with OAC therapy alone. 2 However, these benefits were limited to patients with a mechanical heart valve.
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There was no significant difference in the risk for arterial thromboembolism with these treatments in patients with AF or coronary artery disease, but estimates of treatment effects were statistically uncertain because of the small sample size of the trials. 2 The risk for major bleeding s the unchallenged current treatment of choice for patients wi t th NVAF at moder erat ate e e to o o h h hig ig igh h h r ri ris sk of thromboembolic complications.
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The discrepancy between European and US guidelines is more apparent than real: both recommend combining a vitamin K antagonist (VKA) with one or two antiplatelet agents for up to 12 months depending on type of stent, and both acknowledge a C level of evidence (i.e., expert opinion in the absence of randomized evidence). The only difference is that the authors of the US guidelines state that "the most important agent for the maintenance of coronary and stent patency is the thienopyridine derivative clopidogrel and that the addition of aspirin to the chronic anticoagulant regimen contributes more risk than benefit". 6 The evidence underlying this statement is unclear, in the absence of a randomized head-to-head comparison of clopidogrel versus aspirin in this setting. The recently published American College of Chest Physicians (ACCP) guidelines 1 suggest a graded approach for the first 12 months after intracoronary stent placement based on stroke risk (CHADS 2 score) and type of stent, ranging from dual antiplatelet therapy for AF patients at low to intermediate risk of stroke, to VKA plus dual (first 1-6 months) patients, US guidelines recommend warfarin plus clopidogrel, 6 while European g gu guid id del el lin in nes es 7 7 uggest a triple combination of warfarin, aspirin and clopidogrel for periods of up to 12 months.
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The current US practice of using OAC plus low-dose aspirin in AF patients with stable atherothrombotic vascular disease, largely prescribed by cardiologists and electrophysiologists rather than by primary care providers, 4 may not be unreasonable given the lack of randomized trials in this specific clinical setting and despite the weak recommendations from both US 6 and European 7 guidelines that discourage such practice, because antiplatelet therapy with low-dose aspirin is effective and without major safety concerns in the secondary prevention of atherothrombosis. 5 Moreover, before stopping aspirin because of a new diagnosis of AF and initiation of OAC, or 12 months after an ACS and/or coronary stenting, physicians should carefully consider the potential consequences of unopposed thromboxane-dependent platelet activation following aspirin withdrawal. 9, 10 Thus, in patients prescribed low-dose aspirin for the secondary prevention of cerebrovascular or cardiovascular events, discontinuation of antiplatelet therapy was associated with a 40% increase in the risk of ischemic stroke 9 or myocardial infarction, 10 respectively, compared with continuation of therapy, in UK primary care combined antithrombotic therapy.
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However, the practice of using OAC plus low-dose aspirin in AF patients without symptomatic vascular disease 4 is probably questionable, because of the uncertain balance of cardiovascular benefits and bleeding risks associated with aspirin use in primary prevention, particularly in the elderly. Several new elements should be considered in this evolving scenario: i) the recent marketing of three new OAC, i.e., dabigatran, apixaban and rivaroxaban, with an improved benefit/risk profile as compared with warfarin; 3 ii) the availability of two additional P2Y 12 blockers, i.e., prasugrel and ticagrelor, with an improved benefit/risk profile as compared with clopidogrel; 14 iii) the introduction of drug-eluting coronary artery stents with a reduced propensity towards thrombosis and the prospect of fully bioresorbable drug-eluting vascular scaffolds; 15 iv) increasing awareness of potential non-vascular health benefits (e.g., prevention of colorectal cancer) of long-term aspirin therapy. 11 It is hoped that these novel therapeutic options and areas of knowledge will be integrated with more widespread assessment of the individual AF patient's ischemic and bleeding risks as well of his/her values and preferences to inform personalized antithrombotic therapy in this setting.
